Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MSPrebiotics is a Canadian biotechnology company focused on the research, development, and production of prebiotic supplements derived from natural sources. The company's core product, MSPrebiotic, is a clinically-studied resistant starch (Type 2) extracted from potatoes that promotes the growth of beneficial gut bacteria. By stimulating the production of short-chain fatty acids, the product supports digestive health, improves regularity, and helps maintain healthy blood glucose levels. MSPrebiotics maintains a vertically integrated operation with its own manufacturing facility located in Manitoba, Canada. Their evidence-based approach is supported by peer-reviewed clinical trials demonstrating the efficacy of their resistant starch in diverse populations. The company targets both the retail consumer market and healthcare practitioners seeking natural interventions for microbiome health.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MSPrebiotics.